Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oragenics Inc
(NY:
OGEN
)
1.150
+0.070 (+6.48%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
235,886
Open
1.030
Bid (Size)
1.090 (3)
Ask (Size)
1.160 (42)
Prev. Close
1.080
Today's Range
1.020 - 1.160
52wk Range
0.8611 - 7.740
Shares Outstanding
5,580,693
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
August 21, 2024
Via
Investor Brand Network
EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury
August 21, 2024
Oragenics completes the formulation and filling of its nasal spray drug, ONP-002, for concussion treatment, aiming to launch a Phase 2a trial.
Via
Benzinga
Performance
YTD
-83.04%
-83.04%
1 Month
+9.52%
+9.52%
3 Month
-43.63%
-43.63%
6 Month
-19.58%
-19.58%
1 Year
-61.47%
-61.47%
More News
Read More
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
August 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
August 14, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
OGEN Stock Earnings: Oragenics Reported Results for Q2 2024
August 12, 2024
Via
InvestorPlace
OGEN Stock Earnings: Oragenics Reported Results for Q4 2023
June 28, 2024
Via
InvestorPlace
Why Oragenics (OGEN) Shares Are Falling
June 25, 2024
Via
Benzinga
OGEN Stock Earnings: Oragenics Reported Results for Q1 2024
May 15, 2024
Via
InvestorPlace
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
August 09, 2024
Via
FinancialNewsMedia
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
August 08, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 25, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 05, 2024
Via
Benzinga
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
May 22, 2024
Via
Benzinga
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 22, 2024
Via
Benzinga
Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings
May 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 07, 2024
Via
Benzinga
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
April 19, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
April 01, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
March 18, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
March 05, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Closing of Public Offering
March 01, 2024
From
Oragenics, Inc.
Via
Business Wire
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
February 28, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.